common.study.topics.clinical

Escitalopram for Agitation in Alzheimer's Disease

common.study.values.description

Escitalopram for Agitation in Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Escitalopram

5-15 mg/day (target: 15mg/day if tolerated)

Drug - Placebo

Masked placebo

participant.views.study.view.additional

participant.views.study.view.scientific-title

Escitalopram for Agitation in Alzheimer's Disease

common.study.values.clinical-trial-id

NCT03108846

participant.views.study.view.id

lej9ld